생체재료학회지 (Biomaterials Research)

  • 제16권1호
  • /
  • Pages.19-24
  • /
  • 2012
  • /
  • 1226-4601(pISSN)
  • /
  • 2055-7124(eISSN)
한국생체재료학회 (Korean Society for Biomaterials)
권호 표지

록소프로펜이 함유된 경피 패치의 제조 및 평가

Preparation and Evaluation of Transdermal Patch Containing Loxopropen sodium

  • 하승우 (한국화학연구원 대사증후군 치료제 연구그룹) ;
  • 김수지 (한국화학연구원 대사증후군 치료제 연구그룹) ;
  • 윤지영 (한국화학연구원 대사증후군 치료제 연구그룹) ;
  • 박영택 (대화제약) ;
  • 서중기 (대화제약) ;
  • 박은석 (성균관대학교 약학대학) ;
  • 육순홍 (고려대학교 약학대학) ;
  • 신병철 (한국화학연구원 대사증후군 치료제 연구그룹) ;
  • 조선행 (한국화학연구원 대사증후군 치료제 연구그룹)
  • Ha, Seung Woo (Metabolic Syndrome Therapeutics Research Group, Korea research institute of chemical technology) ;
  • Kim, Suji (Metabolic Syndrome Therapeutics Research Group, Korea research institute of chemical technology) ;
  • Yoon, Ji Young (Metabolic Syndrome Therapeutics Research Group, Korea research institute of chemical technology) ;
  • Park, Yeong Taek (DAE HWA Pharmaceutical Co., Ltd.) ;
  • Seo, Jung Ki (DAE HWA Pharmaceutical Co., Ltd.) ;
  • Park, Eun Suk (School of Parmacy, University of SungKyunKwan) ;
  • Yuk, Soon Hong (College of Pharmacy, Korea University) ;
  • Shin, Byung Cheol (Metabolic Syndrome Therapeutics Research Group, Korea research institute of chemical technology) ;
  • Cho, Sun Hang (Metabolic Syndrome Therapeutics Research Group, Korea research institute of chemical technology)
  • 발행 : 2012.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Loxoprofen sodium[sodium (${\pm}$)-2-[4-(2-oxocyclopentylmethyl)phenyl]propionate] is non-steroidal anti-inflammatory drug in the propionic acid derivatives group. To develop a novel transdermal drug delivery system of loxoprofen sodium, the effects of various vehicles and penetration enhancers on the skin permeation of loxoprofen sodium from solution formulations were investigated. The permeation rate of loxoprefen sodium through excised Sprague-Dawley rat skin was measured using a franz diffusion cell and keshary-chien diffusion cell at $32{\pm}0.5^{\circ}C$. The solubilities of loxoprofen sodium in various vehicle for enhancer were determined by the equilibrium solubility method. The solubility of loxoprofen increased in the rank order of tween80 > labrasol > tween20 > cremophor > lauroglycol90 > capryol90. In addition, transdermal patch containing loxoprofen sodium provides continuous drug delivery over 24 hours and similar efficacy to the highest recommended dose of oral route drug with improved tolerability.

키워드

참고문헌

  1. A. Terada, S. Naruto, K. Wachi, S. Tanaka, Y. Iizuka and E. Misaka, "Synthesis and anti-inflammatory activity of [(cysloalkylmethyl) phenyl]acetic acid and related compounds," Journal of Medicinal Chemistry, 27, 212-216 (1984).
  2. T. Amako, N. Takagish, T. Hiruzaki, Y. Sugioka, K. Takagish and K. Suzuki, "Evaluation of clinical effect of loxoprofen on cervicobrachial syndrome and perathritis of the shoulder," Rinsho To Kenkuy, 62, 214-229 (1985).
  3. T. Aoki, S. Sugawara, T. Hoshino and M. Yamamoto, "Evaluation of elinical effect of loxoprofen on osteoarthritis of the knee," Igaku No Yyumi, 136, 983-1001 (1986).
  4. M. Igarashi, N. Ogawa and T. Nobunaga, "Double blind evaluation comparing CD-600 (loxoprofen sodium) and indomethacin in the treatment of rheumatoid arthritis," Ryumachi, 25, 61-72 (1985).
  5. E. Misaka, T. Yamaguchi, T. Iizuka, K. Kamoshida, T. Kojima, K. Kobayashi, Y. Endo, Y. Misawa, S. Kobayashi and K. Tanaka, "Antiinflammatory antipyretic and analgesic activities of a new antiinflammatory agent: sodium-2[4-(2-oxocyclopentan-1-1-methly) phenyl]propionate dehydrate (CS-600)" Pharmacometrics, 21, 753-771 (1981).
  6. R. Denis, S. Myriam, S. Angela, O. Marc, A. M. Joseph and S. L. Chun, "Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2," Bioorganic & Medicinal Chemistry Letters, 14, 1201-1203 (2004).
  7. T. S. Kim and I. K. Chun, "Formulation and evaluation of loxoprofen plasters," The journal of applied pharmacology, 9, 298-306 (2001).
  8. A. F. Kydonieus, "Fundametal of transdermal drug delivery: in transdermal delivery of drugs," CRS Press, 1, 3-28 (1987).
  9. R. H. Guy, "Current status and future prospects of transdermal drug delivery," Pharmaceutical research, 13, 1765-1769 (1996).
  10. T. K. Ghosh and W. R. Pfister, "Transdermal and topical delivery systems: An overview and future trends: in transdermal and topical drug delivery system," Interpharm press, Inc., 1-32 (1997).
  11. Y. M. Chien, "Advances in transdermal systemic medication: in transdermal controlled systemic medication, Marcel Dekker. Inc., 1-21 (1987).
  12. H. M. Wolff, "Optimal process design for the manufacture of transdermal drug delivery systems," Pharmaceutical Science & Technology today, 3, 173-181 (2000).
  13. H. Seo, S. Y. Jeung, J. S. Park, B. C. Shin, S. J. Hwang and S. H. Cho, "The effect of enhancer on the penetration of indapamide through hairless mouse skin," Journal of Korean Pharmaceutical Sciences, 37, 237-242 (2007).